Emory University-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013576)
◆英語タイトル:Emory University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013576
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:58
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Emory University (Emory) is an educational service provider that offers academic degrees and programs through its arts colleges and graduate and professional schools. The university offers degree programs in the areas of business, law, medicine, nursing, public health, theology, and online courses and programs. It operates new faculties across all the schools which include AIDS, Alzheimer’s, cancer, cardiology, diversity, economics and finance, global health, health, infectious diseases, influenza, neuroscience, pediatrics, politics, psychiatry, psychology, public health, religion and ethics, research, science and surgery. The university also operates research facilities. Emory is headquartered in Atlanta, Georgia, the US.

Emory University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Emory University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Emory University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Emory University, Medical Devices Deals, 2011 to YTD 2017 10
Emory University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Emory University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 13
AKESOgen and Emory University School of Medicine Enter into Partnership 14
Medibio Enters into Agreement with Emory University 15
Defense Threat Reduction Agency Enters into Contract with Emory University 16
Spotlight Innovation Enters into Research Agreement with Emory University 17
Emory University And Children’s Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 18
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 19
Emory University Enters Into Joint Venture With UniQuest To Form Que Oncology 20
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 21
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 22
Rockland Immunochemicals Enters Into An Agreement With Emory University 23
Licensing Agreements 24
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 24
Meissa Vaccines Enters into Agreement with Emory University for Rhinovirus Vaccine 26
Meissa Vaccines Enters into Agreement with Emory University for RSV Vaccine Technologies 27
Incysus Enters into Licensing Agreement with Emory University, Children’s Hospital of Atlanta and University of Alabama at Birmingham 28
Cambium Medical Technologies Enters into Licensing Agreement with Emory University 29
Cocrystal Pharma Enters into Licensing Agreement with Emory University 30
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 31
Carrick Therapeutics Enters into Licensing Agreement with Emory University 32
Genomind Enters Into Licensing Agreement With Emory University 33
RayBiotech Enters Into Licensing Agreement With Emory University 34
Metaclipse Therapeutics Enters Into Option For License Agreement With Emory University 35
Acquisition 36
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 36
Emory University – Key Competitors 37
Emory University – Key Employees 38
Emory University – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Joint Venture 41
Recent Developments 42
Government and Public Interest 42
Sep 25, 2017: Georgia Clinical Translational Science Alliance receives $51 million NIH state-wide grant 42
Sep 07, 2017: NIH awards nearly $100 million for Autism Centers of Excellence program 45
Aug 29, 2017: Morehouse School of Medicine Joins the NIH All of Us Research Consortium 47
Aug 25, 2017: Study identifies genes linked to better immune response to flu vaccine 48
Aug 24, 2017: Lower blood pressure targets for older adults may offer cognitive benefits, study suggests 49
Aug 23, 2017: Cancer drug discovery: Targeting DNA repair 50
Jan 20, 2017: South African Study Provides Compelling New Evidence on Role of Person-to Person Transmission in Drug-Resistant TB Epidemics 51
Nov 16, 2016: Antiviral Success Makes Some Immune Cells Strikier 52
Jun 07, 2016: NIH Awards Emory $35.6 Million Grant for Research Aimed at HIV/AIDS Vaccine and Cure 53
Mar 29, 2016: Three-stage delivery of platinum-based cluster bombs against cancer 54
Feb 09, 2016: Cigna Foundation Makes Community Health Navigation A U.S. Priority; Announces World Of Difference Grant To Emory University, Atlanta 55
Jan 12, 2016: New NIH awards will support development of therapeutic alternatives to traditional antibiotics 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Emory University, Pharmaceuticals & Healthcare, Key Facts 2
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Emory University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Emory University, Deals By Therapy Area, 2011 to YTD 2017 9
Emory University, Medical Devices Deals, 2011 to YTD 2017 10
Emory University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 13
AKESOgen and Emory University School of Medicine Enter into Partnership 14
Medibio Enters into Agreement with Emory University 15
Defense Threat Reduction Agency Enters into Contract with Emory University 16
Spotlight Innovation Enters into Research Agreement with Emory University 17
Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 18
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 19
Emory University Enters Into Joint Venture With UniQuest To Form Que Oncology 20
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 21
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 22
Rockland Immunochemicals Enters Into An Agreement With Emory University 23
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 24
Meissa Vaccines Enters into Agreement with Emory University for Rhinovirus Vaccine 26
Meissa Vaccines Enters into Agreement with Emory University for RSV Vaccine Technologies 27
Incysus Enters into Licensing Agreement with Emory University, Children’s Hospital of Atlanta and University of Alabama at Birmingham 28
Cambium Medical Technologies Enters into Licensing Agreement with Emory University 29
Cocrystal Pharma Enters into Licensing Agreement with Emory University 30
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 31
Carrick Therapeutics Enters into Licensing Agreement with Emory University 32
Genomind Enters Into Licensing Agreement With Emory University 33
RayBiotech Enters Into Licensing Agreement With Emory University 34
Metaclipse Therapeutics Enters Into Option For License Agreement With Emory University 35
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 36
Emory University, Key Competitors 37
Emory University, Key Employees 38
Emory University, Subsidiaries 40
Emory University, Joint Venture 41

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Emory University-製薬・医療分野:企業M&A・提携分析(Emory University - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆